News and Announcements
Mobilicom are pleased to announce they will present at TechKnow Invest Roadshow
- Published October 16, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Mobilicom Limited will present at TechKnow Invest Roadshow.
- TechKnow Invest Roadshow is one of Australia’s leading, premier technology investor events.
- Mobilicom will have the opportunity to network with a highly diverse investment audience.
Mobilicom Limited are pleased to announce that they will be presenting at one of Australia’s premier technology investor events, TechKnow.
TechKnow provides the opportunity to reach out to highly diverse investment audiences including institutional investors, brokers & private investors.
Mobilicom’s CEO, Oren Elkayam will present at the event and will provide an insight into the company’s growth strategy, key company achievements and milestone targets for the financial year 18-19.
As part of the conference, Mobilicom will also take part in one-on-one meetings with investors.
TechKnow is being held at the Radisson Blu Hotel in Sydney on 30 October and at the Grand Hyatt Hotel in Melbourne on 1 November.
About Mobilicom Limited (ASX: MOB)
Mobilicom designs, develops and markets solutions for mission critical and remote mobile private communication networks without the need for, or use of, any existing infrastructure. Mobilicom’s products and technology merge 4G communication with Mobile MESH technologies into a unified solution, with several product families that have been commercially deployed. Mobilicom’s SkyHopper entity targets the Professional, Commercial and Industrial UAV market.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
